prediction of SGA and IUGR may improve the identification of this at risk group and assist in customising the surveillance plan.
Objectives:
Affecting approximately 10% of all pregnancies, intrauterine growth restriction (IUGR) based on impaired placental function, is the most important cause of perinatal mortality and morbidity. So far, there is no option for secondary prophylaxis once signs of insufficient transformation of the uterine arteries and mal-perfusion of the placenta are observed in the second trimester. Clinical management in pregnancies at risk is restricted to close monitoring and assessment for optimal timing of delivery. In a prospective randomised controlled trial patients eligible to such prophylaxis were given the organic nitrate pentaerythrityl-tetranitrate (PETN) (2x80 mg) or placebo (Schleussner et al, J Perinat Med 2014) .
Methods: We could demonstrate an absolute risk reduction of 39% (relative risk RR=0.609, 95% CI 0.367 to 1.011) for the development of IUGR or combined outcome (IUGR or death) (RR=0.615, 95% CI 0.378 to 1.000), respectively. To confirm these results a prospective randomised placebo controlled double-blinded multicentre trial was now initiated.
Approach: Eligible patients are pregnant women at risk of developing IUGR meeting the inclusion criteria: abnormal uterine artery Doppler ultrasound, defined by a mean PI greater than 1.6, singleton pregnancy, informed consent and 19 0 to 22 6 weeks of gestation. Results: Outcome measures: Primary efficacy endpoint: Development of IUGR (defined by birth weight < 10th percentile and impaired uterine perfusion identified by a mean PI of > 1.6). Key secondary endpoint(s): severe morbidity and mortality as composite of severe IUGR (< birth weight below the 3rd centile), intrauterine or neonatal death or placental abruption, birth weight below the 3rd, 5th and 10th centile, preterm birth and neonatal outcome. Objectives: Several studies have compared cross-sectional non-invasive techniques for the measurement of cardiac output (CO) in pregnant women, but studies with longitudinal design are lacking. We aimed to compare the ability of two devices, Vicorder ® and Innocor ® , in tracking changes in CO from pre-pregnancy to post-partum in healthy women. Innocor has previously been validated against invasive techniques but not Vicorder. Methods: Non-smoking women, between 18-44 years, with BMI <35 were selected from a prospective ongoing study (CONCEIVE) on cardiovascular function from prior to pregnancy to post-partum 2014-2017. For data analysis, only healthy pregnancies were included. Measurements were obtained using Vicorder first, and then Innocor under standardised conditions, and repeated at 6 time points (non-pregnant, 6, 10, 22, and 34 weeks gestation, and post-partum). The difference in CO values obtained between time points ( CO) were calculated (15 CO per participant for each device). We used a four-quadrant plot with exclusion zone of 0.5 L/min and calculated concordance rate, angular bias and radial limits of agreement (LOA). A concordance rate of 85% was considered acceptable. By using a linear mixed model analysis we tested whether the longitudinal change in CO differs between the two devices. Results: 69 participants were included (1035 measurements). The concordance rate was 64%, angular bias 0.6836 and radial LOA 12.87-77.13. The longitudinal trajectory of CO recorded with the two devices differed significantly (p=0.0093). The maximum rise in CO happened in the late 1st-beginning of 2nd trimester, however with Innocor it increased by 15% compared to pre-pregnancy values and with Innocor by 7% only. Conclusions: Despite low angular bias, a low concordance rate suggests that the agreement between devices is poor; therefore, they shouldn't be used interchangeably within the same subject through pregnancy. Interestingly, the increase in CO from prior to pregnancy with both devices appears more modest than previously reported.
